Risks and Benefits of Activated Protein C Treatment for Severe Sepsis
- 26 September 2002
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (13), 1027-1030
- https://doi.org/10.1056/nejmsb020574
Abstract
A new hypothesis with implications for the treatment of sepsis has recently been tested — the hypothesis that part of the pathophysiology of sepsis is caused by unrestricted or inappropriate coagulation in the microcirculation. Three agents that block coagulation at different stages have now been evaluated in large, multicenter trials as adjunctive therapy for sepsis. Neither antithrombin III nor tissue-factor-pathway inhibitor was effective in patients with severe sepsis or septic shock.1,2 In contrast, treatment with activated protein C (drotrecogin alfa [activated]) was associated with a significant reduction in 28-day mortality. Of the patients who received activated protein C, 24.7 . . .Keywords
This publication has 10 references indexed in Scilit:
- Treating SepsisNew England Journal of Medicine, 2002
- Activated Protein C for Severe SepsisNew England Journal of Medicine, 2002
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- Inter-observer variability in APACHE II scoring: effect of strict guidelines and trainingIntensive Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- The sirens' songs of confirmatory sepsis trialsCritical Care Medicine, 1998
- Anti-inflammatory therapies to treat sepsis and septic shockCritical Care Medicine, 1997
- Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell LinesNature Biotechnology, 1990
- Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.JCI Insight, 1987
- APACHE IICritical Care Medicine, 1985